The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / FDA Approves Celecoxib in an Oral Solution

FDA Approves Celecoxib in an Oral Solution

June 8, 2020 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF
Maxx-Studio / shutterstock.com

Maxx-Studio / shutterstock.com

On May 6, the U.S. Food & Drug Administration (FDA) approved a 25 mg/mL dose of an oral solution of celecoxib (Elyxyb) to treat adults with acute migraine with or without aura.1 Although not FDA approved to treat other types of pain, the non-steroidal anti-inflammatory drug (NSAID) possibly be used off label for pain management in patients unable to swallow solid dosage forms.

You Might Also Like
  • FDA Approves Oral Methotrexate; Plus Restrictions for 2 Analgesics in Children
  • FDA Approves Combination Therapy for OA Pain, but Not Duobrii Lotion for Plaque Psoriasis
  • Drug Safety: Fasinumab Evaluated in Clinical Trials, Plus Celecoxib May Not Pose Increased Heart Attack or Stroke Risk
Explore This Issue
July 2020
Also By This Author
  • Phase 3 Studies Evaluate Lesinurad for Gout Treatment

The solution carries the same boxed warnings as celecoxib (Celebrex) in its original capsule formulation.2,3 These warnings include an increased risk of serious cardiovascular thrombotic events, such as myocardial infarction and stroke, which can be fatal. This risk may occur early during use and may increase with duration of use. Like celecoxib in a capsule, the oral solution is also contraindicated in the setting of coronary artery bypass graft surgery. Additionally, NSAIDs cause an increased risk of serious gastrointestinal adverse events, such as bleeding, ulceration and perforation of the stomach or intestines, which can be fatal. These events may occur at any time during use and without warning.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Elderly patients and patients with a prior history of peptic ulcer disease and/or gastrointestinal bleeding are at greater risk for these serious events.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Dr. Reddy’s Laboratories. News release: Dr. Reddy’s Laboratories received approval for their NDA, Elyxyb (celecoxib oral solution) 25 mg/mL, in the U.S. 2020 May 6.
  2. U.S. Food & Drug Administration. Prescribing information eylxyb. 2020 May 5.
  3. U.S. Food & Drug Administration. Prescribing information celebrex. 2019 May 3.

Filed Under: Analgesics, Drug Updates Tagged With: celecoxib, celecoxib (Elyxyb), FDA, Pain Management, U.S. Food and Drug Administration (FDA)Issue: July 2020

You Might Also Like:
  • FDA Approves Oral Methotrexate; Plus Restrictions for 2 Analgesics in Children
  • FDA Approves Combination Therapy for OA Pain, but Not Duobrii Lotion for Plaque Psoriasis
  • Drug Safety: Fasinumab Evaluated in Clinical Trials, Plus Celecoxib May Not Pose Increased Heart Attack or Stroke Risk
  • Rheumatology Drug Updates: Celecoxib and Cardiovascular Safety Trial Results Reviewed

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.